Studying how weight-loss medications affect energy use and body composition in obesity
Observes how semaglutide and tirzepatide affect energy use and body makeup in adults with obesity.
Plain-language title generated from the registry record
Registry title: 24-h Energy Expenditure and Anti-obesity Medication
Key facts
- Where
- Pisa, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07041983, who can take part
Where in Italy
- University Hospital of PisaPisa, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pisa
- Trial code
- NCT07041983
- Record updated
- 5 May 2026
- Original description
This study investigates the long-term effects of anti-obesity medications (Semaglutide and Tirzepatide) on energy metabolism (24-hour energy expenditure and substrate oxidation) and body composition via Dual-energy X-ray absorptiometry (DXA)Read full original descriptionShow less
Effects of Anti-obesity Medications on 24h Energy Metabolism and Body Composition in Patients With Obesity
This study investigates the long-term effects of anti-obesity medications (Semaglutide and Tirzepatide) on energy metabolism (24-hour energy expenditure and substrate oxidation) and body composition via Dual-energy X-ray absorptiometry (DXA)
Inclusion: Body mass index (BMI) >= 30 kg/m² or >= 27 kg/m² with at least one weight-related comorbidity and stable body weight (±2 kg in prior 3 months); informed consent, adherence to study protocol, negative pregnancy test and contraception use (if applicable), and absence of cardiovascular events or end-organ damage.
Exclusion: psychiatric conditions impairing adherence, history of medullary thyroid cancer, pregnancy/lactation; diabetes.